What was once driven by retail hype is now increasingly shaped by doctors, regulators, and pharmaceutical-grade standards. And that shift changes everything for investors.
Where the industry is heading…
The next phase of medicinal cannabis looks increasingly like consolidation in order to become a serious player. Enter Little Green Pharma (ASX:LGP) and the proposed merger with Cannatrek.
Imagine two of Australia’s largest and most successful medicinal cannabis companies combining to create an estimated $112.3 million in annual revenue, effectively three times Little Green Pharma’s standalone revenue scale.
Little Green Pharma contributes an established footprint across 10 export markets, creating an immediate international runway for Cannatrek’s highperforming product portfolio.
The merger pairs one of Europe’s largest medicinal cannabis production facilities, a 21,500m² operation in Denmark with one of Australia’s topselling product portfolios. The real estate alone is a serious size!
This is scale meeting distribution, production meeting demand, directly into global growth channels and the numbers speak for themselves…
In Australia alone, the medicinal cannabis market is projected to surpass $1.0bn sales by 2026.
The total European medicinal cannabis market was worth US$3.5 billion in 2024 and is expected to grow by about 33.6% per year, every year, compounded, until 2032.
That’s extremely fast growth.
A rapidly expanding market and two successful companies combining means…
Capturing margin at every step – controlling the growing, manufacturing, distribution, and clinic operations.
Small players face rising distribution and regulatory costs, including likely increased regulatory costs from imminent TGA reforms. A cashed up company can likely withstand these challenges.
Cannatrek’s robust balance sheet can be used to fund further expansion of LGP’s Danish facility, allowing the new entity to achieve production scale and a return on capital that smaller competitors cannot match.
The Kapitalist Take
Medicinal cannabis is no longer a speculative theme. It’s a developing global healthcare industry.
The Little Green Pharma and Cannatrek merger will control the entire chain from “Seed to Patient” during a time where other plays struggle to survive.
The timeline to the merger is near so stay tuned to find out what happens next.
